About CSL Ltd (ASX: CSL)
CSL Limited is a global biopharmaceutical company engaged in the research, development, manufacture, and distribution of biopharmaceutical products and vaccines across Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and a range of other international markets. The company operates through three segments, CSL Behring, CSL Seqirus, and CSL Vifor, each addressing distinct therapeutic needs across a broad patient population.
CSL Behring focuses on plasma products, gene therapies, and recombinants, serving patients with conditions spanning immunology, hematology, cardiovascular and metabolic disease, respiratory conditions, and transplant medicine. CSL Seqirus manufactures and distributes influenza-related products and provides pandemic preparedness services to governments, while CSL Vifor addresses iron deficiency and nephrology through its dedicated product portfolio. The company also licenses its intellectual property as part of its broader commercial operations. Founded in 1916, CSL Limited is headquartered in Melbourne, Australia.
MFAM Research
- [BUY] CSL Ltd (ASX: CSL) Why Tariff Noise Does Not Change the Buy ThesisApril 8, 2026Hold CSL is a Melbourne-based global biotechnology company that makes plasma-derived therapies, influenza vaccines and iron deficiency and renal care treatments. Institutional sell-side research rates it Buy because the tariff sell-off looks overdone relative to the actual exposure. Only two Swiss-made products, Mircera and Velphoro, face a 15 per cent tariff, while key immunoglobulin, haemophilia, […]
A rules-based approach to leveraged ETFs
See how our quantitative strategy works and who it suits.
Explore the strategyBecome an authorised representative
Advise your clients under an established AFSL without building your own. Choose AR or CAR.
Become an AR or CARLatest Announcements
- CSL (ASX: CSL) – CSL to Defend Class ActionOctober 22, 2026CSL Limited, the biopharmaceutical company listed on the ASX, has disclosed the filing of a class action lawsuit in the Supreme Court of Victoria. The proceeding was filed late on Wednesday 21 October 2026 and names CSL as the defendant in respect of alleged breaches during a 16-month period from February 2025 through May 2026. […]
- CSL (ASX: CSL) – CSL Appoints New Chief Executive OfficerOctober 21, 2026CSL Limited has appointed Deborah Waterhouse as Chief Executive Officer and Managing Director, effective 1 February 2027, following an extensive global search conducted by the Board. Waterhouse brings more than 25 years of experience managing complex global specialty pharmaceutical companies across multiple regions. She currently serves as Chief Executive Officer of ViiV Healthcare, a joint […]
- CSL (ASX: CSL) – CSL signs exclusive Alentis Therapeutics dealOctober 5, 2026CSL Limited has entered an exclusive agreement with Alentis Therapeutics to co-develop and co-promote lixudebart, a potential first-in-class treatment for rare kidney and liver diseases. The company will pay Alentis an upfront sum of US$355 million, with potential milestone payments of up to US$1.2 billion as the program advances through clinical trials and toward commercialisation. […]
- CSL (ASX: CSL) – CSL Files FY2026 Results PresentationAugust 18, 2026CSL Limited has released its FY26 results marked by significant portfolio impairments that obscured underlying operational progress. The company reported a net loss of $2.6 billion on revenue of $15.8 billion, but underlying net profit after tax reached $2.8 billion, reflecting the company’s actual operational performance after adjusting for $7.1 billion in non-cash impairment charges, […]
- CSL (ASX: CSL) – CSL FY2026 Results Part 5August 18, 2026CSL Limited reported FY2026 results that mask a complex underlying story. While the reported loss of US$2.6 billion appears dramatic, this reflects US$7.1 billion in impairments rather than operational collapse. Underneath, the company achieved underlying NPATA of US$3.1 billion on revenues of US$15.8 billion, with cash generation of US$3.5 billion from operations. Management characterizes FY26 […]
- CSL (ASX: CSL) – CSL Files FY2026 Statutory AccountsAugust 18, 2026CSL Limited has reported a statutory net loss of US$2.579 billion for the financial year ended 30 June 2026, representing a swing of 186% from the prior year’s profit of US$3.219 billion. This dramatic reversal signals significant one-off charges, impairments, or amortisation expenses that substantially outweighed the company’s underlying operational performance. The underlying NPATA, which […]
- CSL (ASX: CSL) – CSL Enhanced Plasma Manufacturing UpdateJuly 29, 2026CSL Limited has announced plans to launch clinical trials evaluating its next generation Horizon 2 manufacturing process for immunoglobulin production. The company’s move signals progress toward regulatory approval of a technology that could meaningfully enhance operational efficiency and production capacity across its plasma-based business, a key driver of profitability in the coming years. Horizon 2 […]
- CSL (ASX: CSL) – Interim CEO 90 Day Review and Financial UpdateMay 11, 2026CSL Limited has downgraded its FY26 financial guidance following interim Chief Executive Gordon Naylor’s 90-day review of the company, revising expected revenue to around $15.2 billion and NPATA (excluding restructuring costs and impairments) to approximately $3.1 billion, both on a constant currency basis. This represents a material reduction from previous expectations and signals that benefits […]
Financial Summary
Price History
Related Stocks
| Same Industry — Healthcare | Same Sub-Industry — Biotechnology |
|---|---|